A quick note before we begin. This article uses a fleet metaphor to describe how cholesterol moves through the body: a network of tiny vehicles — lipoproteins — each with a job, a route, and an identifying tag on the outside. This morning on my other publication, The Integrative Cardiologist, I published a short overview of that same map for a general audience. It runs about a ten-minute read and introduces the vocabulary this article assumes. If any of what follows feels unfamiliar, that piece is the shortest path in. Cholesterol Fleet Article

The Short Version

• Menopause is a biologically distinct transition, not just aging. It can measurably change your cardiovascular risk picture in a compressed window of midlife.

• LDL cholesterol and apoB tend to rise across the menopausal transition, above and beyond what aging alone predicts.

• HDL cholesterol may stay stable or rise slightly — but that is not a free pass. HDL biology can shift in ways the headline HDL number cannot show.

• Lp(a) is mostly inherited and mostly stable, but can drift modestly upward across the transition. If it has never been checked, ask for it once.

• Visceral abdominal fat, insulin resistance, triglyceride-rich remnants, and blood pressure often shift in the wrong direction at the same time. This is biology, not a discipline problem.

• Early menopause (before ~45) and premature menopause (before 40) deserve earlier and more careful cardiovascular attention, including apoB, Lp(a), and a considered conversation about CAC scoring when a prevention decision is otherwise uncertain.

• What helps most: an anti-inflammatory eating pattern, aerobic and resistance training, sleep and blood pressure care, and — when appropriate — statins or other apoB-lowering therapy. A medication is not a failure of lifestyle.

• Bring to your next visit: current lipid panel with trend, apoB or non-HDL cholesterol, Lp(a) once, blood pressure, waist circumference, and a direct question about whether your current plan is strong enough for your actual risk.

Heart disease risk in women famously “catches up” after menopause. The old shorthand—estrogen protects, then estrogen leaves—captured part of the story. The more useful story is that, over the menopausal transition, the same woman can become a measurably different cardiovascular patient: different particles in circulation, different metabolic pressures, and different traffic patterns through the whole network.

These changes are related to menopause itself, not simply to getting older. The menopausal transition is associated with rises in LDL cholesterol and apoB-containing particles, shifts toward more abdominal visceral fat, worsening insulin sensitivity in some women, and upward drift in blood pressure. The size of these changes varies from woman to woman, but the pattern is real.[^1][^2]

This article is about what changes in the fleet, why a standard lipid panel can become less complete as a map of risk after menopause, and what to ask for at your next visit.

If you already read the Sunday overview or the three-part Cholesterol Transit Authority series on The Integrative Cardiologist, you already have the map—skip to Section 3.

A Quick Map for Everyone Else

Your body does not move cholesterol as a loose substance floating through the blood. It moves cholesterol as cargo, wrapped in tiny vehicles called lipoproteins.

Think of them as a city transit system. Some vehicles carry cholesterol from place to place. Some carry triglycerides from the liver to tissues that need energy or storage. A cleanup fleet helps move cholesterol back toward the liver. Each vehicle has a job, a route, and an identifying protein tag—an apolipoprotein—that tells the body what it is and what to do with it.

The tag that matters most for atherosclerotic cardiovascular risk is apoB. ApoB marks the particles most capable of entering and becoming trapped in artery walls: VLDL and its cholesterol-rich remnants, IDL, LDL, and Lp(a).

Each of these particles carries one apoB-100 molecule. That means an apoB blood test is a close estimate of how many atherogenic particles are circulating in your bloodstream.

LDL cholesterol tells you how much cholesterol is being carried. ApoB tells you, more nearly, how many plaque-capable vehicles are on the road.

Almost every intervention that directly lowers atherosclerotic risk reduces the burden of apoB-containing particles. Medicines such as statins, ezetimibe, and PCSK9-targeting therapies lower particle production or improve particle clearance. Food patterns can influence cholesterol absorption, LDL-receptor activity, triglyceride-rich lipoproteins, and body weight. Exercise works more broadly: it improves fitness, blood pressure, insulin sensitivity, triglycerides, and body composition, even when its direct effect on LDL cholesterol or apoB is modest.

The menopause transition can push several of these systems in the wrong direction at the same time.

What Estrogen Was Doing

Before menopause, estrogen is associated with a generally more favorable cardiometabolic profile.

It appears to support LDL clearance by the liver, in part through effects on LDL receptors and PCSK9 biology. LDL receptors are the liver’s “depot stations”: they pull LDL particles out of circulation. PCSK9 is a protein that reduces the number of functioning LDL receptors. Less PCSK9 activity generally means more LDL receptors remain available to clear LDL from the blood.

Estrogen also influences fat distribution, triglyceride metabolism, blood-vessel function, and—in some women—Lp(a). As ovarian hormone levels become more variable during perimenopause and then decline after menopause, these favorable settings often shift. The direction of change is predictable; the size of change is individual.[^3][^4][^5]

As the transition unfolds, several risk-related systems can move together:

• LDL cholesterol and apoB tend to rise

• Visceral abdominal fat becomes more likely to accumulate

• Insulin sensitivity may worsen

• Triglycerides and triglyceride-rich remnants may rise

• Blood pressure often begins to drift upward

This is why the postmenopausal cardiovascular shift is not simply a matter of “you got older.” Menopause is a biologically distinct transition that can change the risk picture in a relatively compressed period of midlife.[^2][^1]

What Happens to Lipids

For a long time, it was difficult to separate what menopause does from what simple aging does. Both are happening at the same time to the same women.

The Study of Women’s Health Across the Nation—known as SWAN—was designed to help answer that question. It is a long-running, multi-ethnic study that has followed women across the menopausal transition.

The clearest finding is that total cholesterol, LDL cholesterol, and apoB rise specifically during the menopausal transition, above and beyond what chronological aging alone predicts. Triglycerides also often rise, but triglycerides increase with aging in both sexes, so the menopause-specific contribution is less clean.[^6][^2]

In fleet terms: more apoB-tagged vehicles can be on the road, and LDL particles may remain in circulation longer because the liver is clearing them less efficiently.

What this means practically:

• A lipid panel drawn at 45 and one drawn at 52 may reflect meaningfully different biology, even if your eating and exercise habits look much the same.

• A gradual rise in LDL-C, non–HDL-C, or apoB across five to ten years can matter, even when the change on any one annual panel looks small.

• A normal panel before the final menstrual period does not guarantee that the same pattern will continue afterward.

• Lipids deserve renewed attention during perimenopause and after menopause. The right testing interval depends on baseline numbers, family history, metabolic health, and whether treatment decisions are being considered.

If your lipid panel looks quietly worse in your early 50s than it did in your late 40s, and nothing obvious about your lifestyle changed, menopause-related biology may be part of the explanation.

A conventional lipid panel does not become inaccurate after menopause. But it can become less complete as a map of risk—especially if a reassuring HDL-C distracts from rising LDL-C, non–HDL-C, apoB, triglyceride-rich remnants, blood pressure, or Lp(a).

HDL: A Higher Number Is Not a Free Pass

This is one of the more surprising parts of the transition.

After menopause, HDL cholesterol—the number often called “good cholesterol”—may stay stable or rise slightly. A woman looking at her lab report might reasonably conclude that at least this part of the panel is reassuring.

The problem is that HDL cholesterol is only a measurement of the cholesterol carried within HDL particles. It is not a direct test of HDL’s ability to remove cholesterol from tissues, interact with the artery wall, or protect against atherosclerosis.

In SWAN Heart analyses, the relationship between HDL measures and early atherosclerosis appeared to change across the menopausal transition. HDL particle patterns and HDL-related biology may become less favorable in some late-perimenopausal and postmenopausal women, even when the headline HDL-C number remains normal or high.[^7][^2]

That does not mean a standard HDL cholesterol result can diagnose “good” or “bad” HDL in an individual person. HDL-function tests are not standard tools in everyday clinical practice.

The practical message is simpler:

A normal or high HDL cholesterol number after menopause is not a free pass.

Do not let a reassuring HDL-C number become the reason you or your clinician relax about LDL-C, non–HDL-C, apoB, triglycerides, Lp(a), blood pressure, blood sugar, smoking, family history, or overall cardiovascular risk.

Lp(a): The Vehicle to Find

Lp(a)—pronounced “L-P-little-a”—is an inherited LDL-like particle with an extra protein, called apo(a), attached to it.

It carries cholesterol that can enter the artery wall, and its structure is linked to arterial inflammation and clot-promoting biology. Lp(a) is one reason two people with the same LDL cholesterol can have meaningfully different cardiovascular risk.

Lp(a) level is determined predominantly by inherited variation in the LPA gene. It is usually fairly stable through adult life and is not substantially lowered by diet or exercise. Kidney disease, inflammatory states, hormonal changes, and measurement issues can influence a result, but genetics sets the baseline for most people.[^5]

The menopause nuance is important: Lp(a) is not perfectly fixed across the female life course.

Published studies have often found that Lp(a) rises modestly during or after the menopausal transition, although results are not identical across all studies. Some of the variation may reflect aging, individual biology, ethnicity, hormone exposure, and differences in laboratory measurement. Newer longitudinal work suggests that women with intermediate premenopausal Lp(a) levels may be more likely than others to have a clinically meaningful increase through the transition.[^8][^9][^5]

The honest interpretation is this:

• Menopause does not usually create a new severe Lp(a) problem out of nowhere.

• In many women, Lp(a) may rise modestly across the transition.

• The genetic starting point remains much more important than the average menopause-related change.

• Menopause is often a useful moment to discover an elevated Lp(a), because other risk factors may also be shifting.

The practical action is simple:

• If your Lp(a) has never been checked, ask for it once.

• For most people, one measurement is enough for risk assessment.

• Lp(a) usually does not need to be measured every year.

• Your clinician may repeat it if a result sits near a decision threshold, if your circumstances change, or if a treatment that affects Lp(a) is being considered.

• If Lp(a) is elevated, it strengthens the case for paying close attention to LDL-C, non–HDL-C, apoB, blood pressure, smoking, diabetes, and other modifiable risks.

Menopause does not create an Lp(a) problem. But it can be the moment that an inherited risk factor becomes more clinically actionable.

Freight, Waistlines, Metabolism

The lipid panel is not the only system that changes at menopause. Body composition often shifts in ways that reshape the entire traffic pattern.

Visceral fat is fat stored deep in the abdomen around the organs. It differs from the fat stored just under the skin. Visceral fat tends to increase during the menopausal transition, sometimes even when body weight changes little.

This matters because visceral fat is metabolically active. It is associated with worsening insulin sensitivity, higher blood pressure, greater liver production of VLDL particles, and higher triglycerides. Waist circumference, fasting glucose, fasting insulin, and blood pressure may drift upward around the same time.[^1]

In fleet terms, the freight side of the operation starts working harder.

When the liver sends out more VLDL particles, more triglyceride-rich particles circulate. As they unload triglycerides, they leave behind cholesterol-rich remnants. Those remnant particles can also enter artery walls and contribute to atherosclerosis.

This is one reason high triglycerides can matter. Triglycerides themselves are not the main plaque cargo; the concern is often the cholesterol carried in triglyceride-rich remnant particles and the insulin-resistant metabolic setting that produces them.

More VLDL traffic can also be associated with a greater proportion of small, dense LDL particles. But LDL particle size is not the main treatment target.

Small dense LDL is a clue to the metabolic setting, not a treatment target by itself.

The more actionable question is how much overall apoB-containing particle traffic—including LDL, Lp(a), and remnant particles—is circulating.

A postmenopausal panel can sometimes begin to resemble the pattern seen with early metabolic syndrome, even in women who have not dramatically changed their diet or activity. That is a biology change, not a discipline problem.

Treating it as a personal failure is both unhelpful and medically wrong.

Early Menopause Matters

Menopause before age 40—often called premature menopause or primary ovarian insufficiency—and menopause between approximately ages 40 and 45—often called early menopause—deserve special attention.

Premature menopause is recognized in cardiovascular prevention guidance as a risk-enhancing factor. Early menopause is also an important reproductive-history marker that should make clinicians look more carefully at long-term cardiovascular risk.[^10][^11]

This includes menopause that occurs:

• Spontaneously

• After removal of both ovaries

• After chemotherapy

• After pelvic radiation

• In the setting of primary ovarian insufficiency

Earlier loss of ovarian function means more years of exposure to postmenopausal biology. It does not mean a heart attack is inevitable. It means conventional short-term risk calculators may underestimate lifetime risk in some women.

If you went through menopause early, ask for:

• Earlier and more careful attention to LDL-C, non–HDL-C, and apoB

• An Lp(a) measurement if it has not already been done

• Serious attention to blood pressure, glucose, waist circumference, sleep, exercise, and smoking status

• A clinician-guided discussion of whether coronary artery calcium scoring could clarify risk when a prevention decision is uncertain

A coronary artery calcium, or CAC, score is not a routine screening test for every woman with early menopause. It can be useful when the question is whether someone would benefit from more intensive prevention and the answer remains unclear after considering cholesterol, apoB, blood pressure, diabetes, smoking, family history, and other risk enhancers.[^12][^10]

Early menopause is not a footnote in your chart. It belongs in the cardiovascular-risk conversation.

What Helps Most

The prevention levers are not fundamentally different after menopause. What changes is the urgency of using them thoughtfully and measuring whether they are working.

Diet: the overall pattern

The eating pattern that helps after menopause is the same pattern that helps at other stages of life:

• Vegetables, fruit, beans, lentils, and intact whole grains

• Soluble fiber from foods such as oats, barley, beans, lentils, and psyllium

• Nuts, seeds, avocado, and olive oil in place of butter and other saturated-fat-heavy choices

• Fish as a recurring protein choice if you eat fish

• Fewer ultra-processed foods, sugary beverages, refined starches, processed meats, and large portions of saturated-fat-rich foods

After menopause, this pattern is doing double duty. It can help lower LDL-C and apoB while also working against the visceral-fat, triglyceride, insulin-resistance, and blood-pressure shift.

Movement: prioritize both aerobic and strength work

Aerobic exercise remains essential for cardiovascular fitness, blood-pressure control, mood, and metabolic health.

Resistance training deserves special attention during midlife. Training major muscle groups at least twice weekly, when feasible and safe, helps preserve muscle mass, physical function, bone health, and insulin sensitivity.

The goal is not perfection or an intimidating gym routine. The best plan is one that safely includes both aerobic movement and strength work and can be sustained for years.

Sleep, symptoms, and blood pressure

Poor sleep—including sleep interrupted by hot flashes and night sweats—can worsen daily functioning, appetite regulation, blood pressure, insulin sensitivity, and the ability to maintain an exercise routine.

Managing vasomotor symptoms and sleep disruption is important in its own right. Better symptom control may also improve the metabolic environment in which cholesterol and blood pressure are being managed.

That does not mean treating hot flashes has been proven to prevent heart attacks. It means symptom care, sleep care, blood-pressure care, and cardiovascular prevention should not be treated as separate silos.

Medication when appropriate

Statins and other apoB-lowering medicines can meaningfully lower LDL-C and reduce cardiovascular risk in women as well as men when treatment is appropriately indicated.

A medication is not a failure of diet or exercise. It is another way to reduce lifetime exposure to apoB-containing particles when lifestyle alone cannot adequately address inherited risk, existing plaque, diabetes, chronic kidney disease, markedly elevated LDL-C, elevated Lp(a), or another high-risk pattern.

Treatment often begins with a statin when medication is indicated. Ezetimibe, bempedoic acid, and PCSK9-targeting therapies may be added when risk is high, LDL-C or apoB remains above an appropriate target, or statin treatment cannot be sufficiently used or tolerated.

If your LDL-C or apoB is not where your risk profile suggests it should be, ask directly:

“Is my current prevention plan strong enough for my actual risk?”

Hormone therapy is a separate conversation. It can be highly effective for appropriately selected women with menopausal symptoms, but it should not be started solely to prevent cardiovascular disease. That subject deserves its own careful discussion with a clinician who understands both menopause care and cardiovascular risk.

What to Ask For

Bring this checklist to your next visit:

• A current lipid panel, interpreted in the context of your trend over time rather than as one isolated number.

• ApoB if available, particularly when triglycerides are elevated, insulin resistance is present, LDL-C and non–HDL-C do not tell the whole story, or there is concern that LDL-C may underestimate particle burden.

• Non–HDL cholesterol if apoB is not available. It is calculated as total cholesterol minus HDL cholesterol and captures the cholesterol carried in all major apoB-containing particles.

• Lp(a) once, if it has never been measured.

• Blood pressure and waist circumference tracked with the same seriousness as cholesterol.

• Screening for diabetes or prediabetes when appropriate.

• A review of early menopause, premature menopause, preeclampsia, gestational diabetes, autoimmune disease, chronic kidney disease, smoking, and family history of premature cardiovascular disease.

• A conversation about whether a CAC score would genuinely change a prevention decision that is otherwise uncertain. CAC is most useful as a targeted risk-clarification tool, not as a routine test for everyone.[^10][^12]

• A direct question about whether your current LDL-C, non–HDL-C, or apoB warrants medication—or whether existing treatment should be intensified.

The Close

The fleet you rode in your 30s is not necessarily the fleet you are riding at 55.

That is not a failure of anything you did. It is biology.

The women who do best across the menopausal transition are rarely the ones pursuing the most dramatic intervention. They are the ones whose prevention plan changes when their biology changes: who track the trend instead of dismissing a slow rise, measure apoB when it will clarify particle burden, check Lp(a), take blood pressure and visceral-fat accumulation seriously, recognize early menopause as a risk enhancer, and use medication appropriately when lifestyle alone is not enough.

Menopause changes the map.

Your care should change with it.

This article is for patient education. It is not a substitute for individualized medical advice. Cardiovascular and menopause-related care should be directed by your physician using validated risk assessment and current guideline-based therapy.

Key Sources

• El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532.[^1]

• Woodard GA, Brooks MM, Barinas-Mitchell E, Mackey RH, Matthews KA, Sutton-Tyrrell K. Lipids, Menopause and Early Atherosclerosis in SWAN Heart Women. Menopause. 2011;18(4):376-384.[^2]

• Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, Matthews KA. Lipid Changes During the Menopause Transition in Relation to Age and Weight. American Journal of Epidemiology. 2009;169(11):1352-1361. Prospective longitudinal SWAN analysis of lipid changes across the menopause transition.[^6]

• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. Guidance on risk enhancers and the selective use of coronary artery calcium scoring.[^12][^10]

• Corral P, Matta MG, Aguilar-Salinas C, et al. Lipoprotein(a) Throughout Life in Women. American Journal of Preventive Cardiology. 2024.[^5]

• Palmer CA, et al. Heterogeneity in Lipoprotein(a) Profile Changes Across the Menopausal Transition. Longitudinal evidence of variable Lp(a) changes across transition.[^8]

<div align=”center”>⁂</div>

[^1]: https://pubmed.ncbi.nlm.nih.gov/33251828/

[^2]: https://pmc.ncbi.nlm.nih.gov/articles/PMC3123389/

[^3]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7002320/

[^4]: https://www.jlr.org/article/S0022-2275(20)35630-3/fulltext

[^5]: https://www.lipid.org/resource/current-understanding-of-the-contribution-of-lipoproteina-to-atherosclerotic-cardiovascular-disease-risk-in-women/

[^6]: https://pmc.ncbi.nlm.nih.gov/articles/PMC2727246/

[^7]: https://www.ahajournals.org/doi/10.1161/JAHA.121.021362

[^8]: https://pmc.ncbi.nlm.nih.gov/articles/PMC13042140/

[^9]: https://www.sciencedirect.com/science/article/abs/pii/S0378512222002134

[^10]: https://www.ahajournals.org/doi/10.1161/cir.0000000000000678

[^11]: https://www.acc.org/Latest-in-Cardiology/Articles/2026/07/01/01/Prioritizing-Health

[^12]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7685565/

A note before the story. The patients you meet in this newsletter are composites — portraits drawn from patients I have cared for over years, with identifying details changed and the physiology kept honest. Composites let me teach the truth of an exam-room encounter without breaking the trust of the women who lived them. Nothing in this newsletter is medical advice for any individual reader.

The first time I met Jennifer she was 51, 8 months out from her last menstrual period, and sitting in my office because her gynecologist and her primary care doctor could not agree. On the intake sheet she had written my mother had a stent at 68, my father had a bypass at 62, my sister is on a statin, and I am now sleeping 4 hours a night. As my mouse hovered over her appointment slot the reason-for-visit window popped open — clearance for hormone therapy. I could hear the whole story in that sentence before I opened the chart.

The numbers she brought with her were from her primary care’s office and they told a familiar story. At 46 her blood pressure had been 118 over 74 and her LDL cholesterol had been 90. She ran 5 miles four mornings a week. Her dietary inventory was reassuring. For 4 years the numbers had said her prevention plan was working.

Then the ovaries had gone quiet.

The office cuff on the day she came to see me read 138 over 88. What would her home log say? The LDL her primary care doctor had drawn 3 weeks earlier was 130. Nothing in her life had changed except a hormonal signal that had been steady for 30 years.

Her gynecologist had already offered her transdermal estradiol and oral micronized progesterone.

Her primary care doctor had said what a careful primary care doctor learned to say in 2005: not with your family history.

She came to me because both were experienced, both were careful, and both could not be right.

The visit at the intersection of hormone therapy and the heart is a two-decisions visit, not a one-decision visit, and it is the visit I want to walk you through week after week in this newsletter. I want to teach you the version of it I use with Jennifer and with the women who ask her questions in my office. I want to teach you the mechanism at the level the evidence actually supports. I also want to share the art of how I deliver it. I want to teach you what the trial the whole conversation goes back to actually studied. And I want to give you the language to bring back to your own visit.

Before menopause, estrogen is associated with vascular effects involving endothelial function, vascular tone, and lipid metabolism. Menopause is often accompanied by changes in blood pressure, body composition, lipids, and vascular function. Those changes deserve attention, even when diet and exercise have not changed.

Think of your arteries like the pipes inside the walls of a house — the pipes that carry the oxygen and nutrients every organ needs to stay alive. But unlike the pipes in your kitchen, these pipes are alive. They are connected to each other. They talk with each other and with the blood moving through them. And they are lined, on the inside, with a single layer of tiny tiles — one cell thick, laid edge to edge from the aorta all the way out to the smallest capillary. That lining is the endothelium. It is the surface that decides how the pipes behave (and where) — whether it relaxes or tightens, whether it stays smooth or gets sticky, whether the blood that touches it clots or keeps moving. For 30 years of a woman’s reproductive life, circulating estrogen is one of the signals those tiles are listening to. When ovarian estrogen falls at menopause, one of the signals they had been listening to changes. Some women feel it fast. Some do not. The pipes are still there. The tiles are still there. What comes off is one of the signals that had been talking to them, quietly, for 30 years, while she was busy living the rest of her life.

But biology alone does not tell us that starting hormone therapy will prevent heart attacks. That is the sentence the whole rest of this article is built around. Mechanism is not outcome. And the trial that stopped in 2002 is the reason we know it is not.

The Women’s Health Initiative — the trial that shaped how a generation of doctors was taught to think about hormone therapy — was designed and enrolled in the 1990s and stopped its combination-therapy arm early in July 2002. The mean age at randomization in that arm was 63. Only about 3 percent of the women were in their early 50s. Two-thirds were 60 or older. The average woman in the WHI was more than a decade past her last period the day she took her first pill.

That is not a criticism of the WHI. It is an observation about who was in the room. The women in Jennifer’s shoes today are not, on average, 63. They are 48, and 51, and 54. They are inside the first decade after their last period — what the field now calls the window.

In 2007 the WHI investigators went back and stratified the trial by age at initiation. The story that came out of that reanalysis is more careful than the way it has been repeated on the internet since. WHI reanalyses suggested that absolute risks were lower, and the overall balance looked more favorable, among younger women and those closer to menopause. But the trial did not establish hormone therapy as a treatment to prevent coronary disease. The 50-to-59 subgroup coronary heart disease hazard ratio was 0.93, with a confidence interval that crossed 1. Timing matters. But timing did not prove cardiovascular protection.

Timing matters because the balance of benefits and risks of starting systemic therapy is generally more favorable earlier in menopause than when therapy begins after age 60 or more than 10 years after menopause. Later initiation carries higher absolute risks of coronary events, stroke, venous thromboembolism, and dementia than earlier initiation, in part because baseline risks are higher with age and time since menopause.

Major societies have integrated that finding into how they recommend the conversation happen. NAMS. ACOG. The Endocrine Society. The European Menopause and Andropause Society. All of them incorporate age, time since menopause, route, dose, and individual risk into shared decision-making. None of them recommend systemic hormone therapy solely to prevent cardiovascular disease. What all of them do is treat symptomatic women inside the window as candidates for a serious individualized conversation about symptom treatment, and treat systemic therapy started well outside the window as a higher-risk decision that requires a specific reason.

Jennifer’s gynecologist was reading that body of work.

Jennifer’s primary care doctor was reading the summer of 2002.

The gap between those two conversations is the gap this newsletter exists to close. Not by arguing against the primary care doctor — he was, in 2005, reading the most careful summary available. By offering the better mechanism, which is that a woman in Jennifer’s window is a candidate for a serious individualized conversation with her clinicians about symptom treatment and a separate, load-bearing cardiovascular prevention plan.

Before I said anything about whether a trial of systemic therapy was reasonable, I wanted to see her risk picture the way I look at everyone’s risk picture in this seat. Her intake and her exam did not turn up a contraindication. What I still needed were 4 numbers her chart did not yet have. The first was a coronary artery calcium score. The second was a high-sensitivity C-reactive protein. The third was an ApoB — the newer marker I like better than LDL alone because it actually counts the atherogenic particles in her blood rather than the cholesterol riding inside them. The fourth was a lipoprotein(a), the inherited particle every woman with her family history deserves to have measured once in her life.

The first was a coronary artery calcium score. A CAC score is a non-contrast CT scan of the heart that measures calcified plaque (cured spackle) in the coronary arteries. In a woman inside the window, in front of a hormone-therapy decision, it answers a specific question. How much plaque has 51 years of biology, family history, and the recent metabolic shift actually laid down in the pipes? A CAC of 0 in a woman her age is a strong signal of low near-term cardiovascular risk — in the Multi-Ethnic Study of Atherosclerosis the coronary event rate in participants with a CAC of 0 was 0.8 per 1,000 person-years, and the warranty period of a zero score in a woman her age is estimated at roughly 5 to 7 years (MESA, Circulation 2016; MESA, JACC: Cardiovascular Imaging 2021). A CAC in the hundreds moves the risk-benefit conversation for systemic therapy in the other direction — in MESA, participants with a CAC above 100 had a coronary event rate of 20.2 per 1,000 person-years, roughly a 25-fold increase (MESA, Circulation 2016).

The second was a high-sensitivity C-reactive protein. hs-CRP is a downstream marker of systemic inflammation. The categories I use are the ones the AHA and CDC put on the table in 2003 and have not moved since: below 1 mg/L is low cardiovascular risk, 1 to 3 is average, above 3 is high (Pearson et al., Circulation 2003; CDC/AHA workshop follow-up, Circulation 2004). An hs-CRP above 10 mg/L is not read as vascular risk at all until it is repeated 2 weeks later and the person is examined for infection or another acute inflammatory cause (Pearson et al., Circulation 2003). The evidence that hs-CRP identifies a group who benefits from primary prevention comes principally from JUPITER, in which apparently healthy men and women with LDL cholesterol under 130 mg/dL and hs-CRP of 2.0 mg/L or more had a 44 percent reduction in first vascular events on rosuvastatin (Ridker et al., New England Journal of Medicine 2008). hs-CRP does not by itself decide whether hormone therapy is on the table. It changes how carefully I want to watch the tiles in the years ahead.

The third was an ApoB. A standard lipid panel gives you cholesterol concentration — the cargo. Hash marks up the test tube, if you will. Is that test tube filled with particles of sand or particles of gravel? ApoB counts the particles doing the carrying, one apolipoprotein B molecule per atherogenic particle. When cholesterol and particle count agree, either one tells you what you need to know. When they disagree — a normal LDL with a rising ApoB is the classic postmenopausal pattern — the particle count is the number that predicts risk. Her ApoB came back at 102. Once ApoB is on the table, the natural next question is what kind of particles those are. An NMR lipoprofile answers that. NMR gives you the average LDL particle diameter in nanometers, the total number of LDL particles circulating (LDL-P), and — the number I care most about — the count of small dense LDL particles, the subfraction that penetrates the endothelial tiles most easily. For Jennifer, the NMR came back with an average LDL particle size of 21.8 nm — Pattern A — a total LDL-P of 1,279 nmol/L, and a small LDL-P of 283 nmol/L. That is a cleaner picture than her ApoB and her LDL alone would have predicted: the particle count is modest, the particles themselves are the larger, more buoyant kind, and the small dense subfraction — the species that drives the highest per-particle risk — sits at roughly a fifth of her total LDL-P. In prospective cohort data from ARIC, small dense LDL-cholesterol in the highest quartile carried roughly a 50 percent higher risk of coronary heart disease independent of standard risk factors, and predicted risk even in people whose standard LDL-C looked low — the exact scenario a postmenopausal woman with a rising ApoB often finds herself in (Hoogeveen et al., ARIC, Arterioscler Thromb Vasc Biol 2014). LDL particle number by NMR has been shown to add prognostic information beyond LDL-C in the Framingham Offspring cohort as well (Cromwell et al., J Clin Lipidol 2007), and in women specifically in the Women’s Health Study (Blake et al., Circulation 2002). ApoB tells me how big the spackle bucket is. A CAC tells me how much cured spackle is already in the wall (what about uncured plaque? — that is a longer discussion coming in a future week). NMR tells me what is in the bucket.

The fourth was a lipoprotein(a) (a sticky spackle). Lp(a) is a genetically determined atherogenic particle that is fixed for life, largely unmoved by diet, exercise, or standard statin therapy, and a strong independent risk factor for coronary disease when elevated. Because it is inherited, every adult deserves it measured once — and a woman whose mother had a stent and whose father had a bypass deserves it measured this year. Her Lp(a) came back at 34 nmol/L, on the lower end of the normal range. That is one inherited channel of risk we can now stop worrying about.

Jennifer’s CAC came back at 0. Her hs-CRP was 0.7. Her ApoB was 102, with an NMR showing an average LDL particle size of 21.8 nm — Pattern A — a total LDL-P of 1,279 nmol/L, and a small LDL-P of 283 nmol/L. Her Lp(a) was 34 nmol/L. Her home cuff ran 138 over 88 and her LDL was 130, but the pipes themselves had not yet accumulated visible plaque, the inherited channel was quiet, the particles she was carrying were the larger and more buoyant kind, and her inflammatory tone was low. That is a picture in which the near-term risk of a time-limited trial of systemic therapy for symptom treatment is lower than the picture would be in a woman with a CAC of 340, Pattern B particles, an Lp(a) of 180, and an hs-CRP of 4. It is not zero risk. It is a picture in which the balance of benefits and risks moves toward reasonable.

Those 4 numbers are also the numbers we would watch forward whether or not hormone therapy was in the plan. In my practice, when someone in Jennifer’s seat asks about hormone therapy, I am also, in the same visit, asking a bigger question about her pipes.

None of these 4 numbers tell me whether hormone therapy will protect her heart — no test does, because that is not what hormone therapy does. What they tell me is whether the near-term risks of a time-limited trial of systemic therapy for her symptoms are acceptable given her pipes today.

So we made 2 decisions that day, not 1.

The first was about her symptoms. A time-limited trial of systemic therapy was reasonable for symptom treatment. She and her gynecologist would work out the dose, the duration, and the follow-up. Transdermal estradiol is often favored when vascular or VTE risk is a concern because it avoids first-pass hepatic metabolism and may have a more favorable thrombotic profile than the oral form. Oral micronized progesterone is commonly selected because of its tolerability, its endometrial-protection role in a woman with a uterus, and — in a woman sleeping 4 hours — its bedtime sedating effect.

The second was about her prevention plan. That plan did not depend on the first decision. A 2-week home BP log using the protocol I teach in Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication (Cordate Press; Kindle available now, paperback October 20, 2026): validated upper-arm cuff, sit quietly for 5 minutes, take 3 readings in a row and record the lowest, morning and evening. A repeat ApoB at 6 months. A repeat NMR at 12 months. A repeat CAC in 5 years, sooner if the picture changed. Her Lp(a) result went into the chart as a lifetime baseline. A 3-month follow-up on my calendar. Pharmacologic decisions about pressure and lipids deferred to that visit, once the log was in hand.

Hormone therapy was not a substitute for cardiovascular prevention. It never has been. In my practice the visit that gets both decisions right is the visit that treats them as 2 decisions, not 1.

At 3 months her home log ran 122 over 78 — some of that a return of her overall stress load with her sleep restored, some of it what happens when a person starts checking their pressure daily and paying attention. Her sleep had come back to 6 and a half hours. Her hot flashes were down from 6 to 1. Her repeat LDL, at 6 months, was 106 (ApoB 91), a change we interpreted cautiously rather than attributing to one intervention. Her family history and her lipid numbers still required an independent prevention plan. We talked about it at that visit and made the second set of decisions with the second set of numbers.

Her symptoms were better controlled. We had a structured plan to monitor treatment and manage her cardiovascular risk factors. Jennifer was, I told her, going to be watched more carefully than most women her age, because her family had asked us to.

If a woman like Jennifer were in your kitchen tonight, telling you her pressure has climbed 20 points in a year and her sleep is at 4 hours and her gynecologist has offered her a patch and her primary care doctor has said no — there are 3 lines she may be hearing that I want to name for you, because they are the reliable sign that the conversation across the desk has not fully caught up with the current evidence.

You cannot take hormones because your mother had a heart attack. A family history of premature coronary disease is not, by itself, an automatic ban on hormone therapy. It is a reason to assess cardiovascular risk carefully and decide whether systemic therapy is appropriate for symptom treatment. It is also a reason to build a serious prevention plan that would matter whether or not she chose hormone therapy.

The WHI showed hormones cause breast cancer. In WHI, the combined regimen of conjugated equine estrogen plus medroxyprogesterone acetate was associated with an increased breast-cancer incidence; estrogen alone in women with prior hysterectomy had different findings. Risks vary by formulation, progestogen, duration, and patient factors. For the specific WHI combined regimen, the excess was small in absolute terms — often communicated as several additional cases per 10,000 women per year — but it should not be treated as a direct estimate for every modern regimen.

You have to stop at 5 years. There is no universal automatic stop date at 5 years. Duration should be individualized, with periodic reassessment of symptoms, benefits, risks, dose, route, and alternatives.

If you hear any of those 3 lines, none of them is an emergency and none of them is a fight. The move is not to argue harder. The move is to bring the actual clinical question back into the room — given my age, my time since my last period, my cardiovascular risk factors, and my symptom burden, what would a serious individualized conversation look like? — and to ask what your clinician thinks about it. In my practice most of the time the question, once it is in the room, does its own work.

If you are reading this and you are 47 or 51 or 54 and your blood pressure is drifting or your sleep is at 4 hours or your LDL or ApoB has moved for reasons your diet cannot explain, the visit you deserve is the one Jennifer and I built. Two decisions, not one. A symptom-treatment conversation you and your gynecologist, primary care physician, or another clinician comfortable with the current menopause evidence can have. A separate prevention plan for pressure, lipids, and family history that would be the same plan whether or not hormone therapy was on the table. A follow-up on the calendar. A home log. A repeat lipid panel with ApoB. A named next step if it is not working.

I will keep writing about this. Next Tuesday I want to walk you into the WHI itself — what it actually studied, who was in the room, and what the 2 decades since have moved into the shared-decision language of every current major society statement. The week after that, what a real hormone-therapy visit looks like when it is done well. The week after that, we widen the lens, because hormone therapy is 1 of several conversations the window opens, and I want you to know which system moved first for you.

If a friend sent you this and you would like next Tuesday’s post in your inbox, you can subscribe below.

Jennifer is doing well. She still runs. She is still 4 years out from the age at which her father had his bypass. She and I both know that. Her symptoms are better controlled. Her prevention plan is on my calendar. We are watching the numbers together.

Sameer Azhak, MD, FACC is a preventive and integrative cardiologist in Wayne, New Jersey. He writes The Menopause Heart on the cardiovascular half of the menopausal transition. His companion Substack, The Integrative Cardiologist, covers broader preventive cardiology. His books are published by Cordate Press. The blood pressure protocol referenced above comes from his book Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication, available on Amazon Kindle now and in paperback October 20, 2026. This newsletter is educational and is not medical advice for any individual reader.

This publication is written by Sameer Azhak, MD, FACC, a board-certified cardiologist. It is provided for general educational and informational purposes only. It is not medical advice, is not a substitute for professional medical care, and does not create a physician-patient relationship between you and Dr. Azhak, Cordate Press, or Integrative Cardiology LLC.

Do not start, stop, delay, or change any treatment, medication, or supplement based on what you read here. Always consult your own physician about your specific medical situation. Dr. Azhak is licensed only in New Jersey; nothing here constitutes the practice of medicine in any other jurisdiction.

If you think you may be having a medical emergency, call 911 or go to the nearest emergency department immediately.

Please do not send protected health information or clinical questions by email or in comments — those channels are not HIPAA-secure. For the full, canonical disclaimer and privacy policy — including how subscriber data is handled by Substack and this publication — see drazhak.com/medical-disclaimer and drazhak.com/privacy.

Contact

For general questions (not clinical), use the contact form at drazhak.com. For patient care, please schedule with Heart & Vascular Associates at (973) 942-1141.

This page will be kept up to date. Last updated: August 2026.

Not in a scary way. In a this-is-worth-paying-attention-to way.

I’m Dr. Sameer Azhak — a board-certified cardiologist and Fellow of the American College of Cardiology, with a fellowship in Integrative Medicine from the Andrew Weil Center at the University of Arizona. I have spent more than two decades taking care of women whose hearts were quietly changing during perimenopause and beyond — often without anyone connecting the dots. The Menopause Heart is where I connect them.

Why a whole letter for this

Because the story that most women get about menopause is a hot-flash story, a sleep story, or a hormone-replacement story. Those are real. But the cardiovascular chapter tends to get lost, and it shouldn’t:

• LDL (particle number) and ApoB tend to rise across the transition, sometimes sharply.

• Blood pressure often creeps up in ways that don’t get caught for years.

• Arterial stiffness measurably increases.

• Visceral fat redistributes in a way that changes metabolic risk.

• Sleep disruption and vasomotor symptoms are now linked to cardiovascular outcomes, not just quality of life.

• Heart disease becomes the leading cause of death in women — more than all cancers combined.

None of this is destiny. All of it is trackable, modifiable, and worth naming out loud.

What you’ll get here

• Perimenopause and the heart. What actually changes, when it starts, and what to watch for.

• HRT and cardiovascular risk — the honest version. What the current evidence says, where the old WHI story was misread, and how to have the conversation with your doctor.

• The labs your cardiologist should be running at 40. Lp(a), ApoB, hs-CRP, NMR LipoProfile, homocysteine — what they mean and why they matter more now.

• Cholesterol at midlife. Why it rises, whether to worry, and what to do.

• Blood pressure. The silent shift most women miss.

• Sleep, hot flashes, and the vascular system. The link cardiology used to dismiss.

• Anti-inflammatory eating for the midlife heart. Not a diet plan — a pattern.

• Coronary calcium scoring for women. Who benefits, when to ask.

• Supplements marketed to menopausal women. What’s real, what’s not, and what to save your money on.

What this letter won’t do

• It won’t fear-monger. Menopause is a transition, not a diagnosis.

• It won’t tell you what to do. It will tell you what the evidence says so you can decide, with your own doctor.

• It won’t sell you supplements. No affiliate links. Ever.

• It won’t replace medical care. Nothing here creates a doctor-patient relationship.

Why me, and why this letter

Because women deserve cardiology written for them, by a cardiologist who has spent a career in the exam room actually listening. Not repackaged from a general-audience article. Not filtered through a wellness brand. Not fifteen minutes at a rushed appointment.

I write another letter, The Integrative Cardiologist, for a broader audience on preventive and integrative cardiology. This one — The Menopause Heart — is specifically for women in the perimenopause-through-menopause chapter. Both are free. Both are companions. Cross-subscribe if you want both.

What happens next

I’ll be publishing regularly. Expect the first substantive article within the week. If you’re reading this because you found me by name, thank you for being here from day one. If a friend forwarded this, welcome — I hope you stay.

Two small favors:

1. Hit subscribe. It’s free, and it’s how new posts find you.

2. Send this to one woman in your life who is somewhere in the perimenopause window. She almost certainly hasn’t heard this framed as a cardiovascular story. She should.

Your heart has carried you through everything. Let’s make sure it carries you through this chapter, too — clearly, evidence-first, without the noise.

— Dr. Sameer Azhak

Board-certified cardiologist · Andrew Weil Center Integrative Medicine

Wayne, New Jersey

This post is for general educational purposes only. It is not medical advice, is not a substitute for care from your own physician, and does not create a physician-patient relationship. Do not start, stop, or change any treatment based on what you read here. If you think you may have a medical emergency, call 911 or go to the nearest emergency department. Full disclaimer at drazhak.com/medical-disclaimer.